|
62 Companies |
|
89 Products |
|
89 Products |
|
76 Mechanisms of Action |
|
2 Trials |
|
652 News |
|
| «12...234567891011121314» |
- ||| Enrollment open: Shared Decision Making in Graves Disease - Graves Disease (GD) Choice (clinicaltrials.gov) - Apr 3, 2014
P=N/A, N=147, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting
- || New P3 trial: THOP2: Study of Thyroid Hormones in Prematures (clinicaltrials.gov) - Apr 2, 2014
P3, N=1224, Not yet recruiting, Sponsor: New York Medical College
- Enrollment change, Biopsy: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules (clinicaltrials.gov) - Mar 27, 2014
P=N/A, N=735, Completed, Sponsor: Istanbul Science University
Not yet recruiting --> Recruiting N=1000 --> 735
- Trial completion, Biopsy: Prediction of Thyroid Cancer From Ultrasonographic Characteristics of Thyroid Nodules (clinicaltrials.gov) - Mar 27, 2014
P=N/A, N=735, Completed, Sponsor: Istanbul Science University
N=1000 --> 735 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Combination therapy, Surgery, Metastases: Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 20, 2014
P1, N=24, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Mar 19, 2014
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=48 --> 19
- Clinical: Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Birte Nygaard
- imatinib / Generic mfg.
Trial termination: Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma (clinicaltrials.gov) - Mar 18, 2014
P2, N=11, Terminated, Sponsor: University of Michigan Cancer Center
N=48 --> 19 Completed --> Terminated; Study was closed early due to slow accrual
- imatinib / Generic mfg.
Enrollment change: Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma (clinicaltrials.gov) - Mar 18, 2014
P2, N=11, Terminated, Sponsor: University of Michigan Cancer Center
Completed --> Terminated; Study was closed early due to slow accrual N=29 --> 11
- thyroxine / Generic mfg.
New P2/3 trial: Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism (clinicaltrials.gov) - Mar 16, 2014
P2/3, N=50, Completed, Sponsor: Isfahan University of Medical Sciences
- Clinical protocol, New P1/2 trial: Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery (clinicaltrials.gov) - Mar 13, 2014
P1/2, N=50, Not yet recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
- Trial completion: Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer (clinicaltrials.gov) - Mar 12, 2014
P=N/A, N=20, Completed, Sponsor: University of Tartu
N=29 --> 11 Recruiting --> Completed
- | Caprelsa (vandetanib) / Sanofi
Enrollment change, Metastases: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=16, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed N=10 --> 16
- | Caprelsa (vandetanib) / Sanofi
Enrollment closed, Metastases: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma (clinicaltrials.gov) - Mar 11, 2014
P1/2, N=16, Active, not recruiting, Sponsor: AstraZeneca
N=10 --> 16 Recruiting --> Active, not recruiting
- thyroxine / Generic mfg.
Trial completion: Levothyroxine for Children With Euthyroid Sick Syndrome (clinicaltrials.gov) - Mar 3, 2014
P4, N=80, Completed, Sponsor: Sinaloa Pediatric Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| Trial completion: Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy (clinicaltrials.gov) - Feb 26, 2014
P3, N=198, Completed, Sponsor: Green Cross Corporation
Recruiting --> Completed Recruiting --> Completed
- Zybrestat (fosbretabulin) / Oncotelic
Trial initiation date, Combination therapy: FACT2: Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer (clinicaltrials.gov) - Feb 25, 2014
P3, N=0, Withdrawn, Sponsor: OXiGENE
Recruiting --> Completed Initiation date: Jun 2013 --> Mar 2015
- Enrollment change: Spectroscopy With Surface Coils and Decoupling (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=582, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Jun 2013 --> Mar 2015 N=900 --> 582
- Trial completion: Spectroscopy With Surface Coils and Decoupling (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=582, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=900 --> 582 Recruiting --> Completed
- |||| Inlyta (axitinib) / Pfizer
Trial completion, Metastases: Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: Pfizer
Recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients (clinicaltrials.gov) - Feb 22, 2014
P2, N=20, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Recruiting --> Completed
- | celecoxib oral / Generic mfg.
Trial completion, IO biomarker, Metastases: Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=25, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Zybrestat (fosbretabulin) / Oncotelic
Trial completion, Metastases: Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- sorafenib / Generic mfg.
Enrollment change: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Feb 20, 2014
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed N=80 --> 20
- sorafenib / Generic mfg.
Trial completion: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Feb 20, 2014
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
N=80 --> 20 Recruiting --> Completed
- Trial completion: Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules (clinicaltrials.gov) - Feb 20, 2014
P=N/A, N=400, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Combination therapy: Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=29, Completed, Sponsor: Fox Chase Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- | Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion: Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion, Metastases: SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P1, N=12, Completed, Sponsor: Case Comprehensive Cancer Center
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, NN1213 / Novo Nordisk
Trial completion: Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed No longer recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion: Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (clinicaltrials.gov) - Feb 19, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | azacitidine / Generic mfg.
Trial completion, Metastases: Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Lucille P. Markey Cancer Center at University of Kentucky
Active, not recruiting --> Completed No longer recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Grant: Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=30, Completed, Sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology
No longer recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Using X-Ray Dye to Locate Hidden Parathyroid Tumors (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=150, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting --> Completed Recruiting --> Completed
- remifentanil / Generic mfg.
Trial completion: Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=76, Completed, Sponsor: Yonsei University
Recruiting --> Completed Not yet recruiting --> Completed
- sobetirome (QRX 411) / Annovis Bio
Trial withdrawal: Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) (clinicaltrials.gov) - Feb 11, 2014
P1, N=0, Withdrawn, Sponsor: Thomas S. Scanlan
Not yet recruiting --> Completed Recruiting --> Withdrawn
- sobetirome (QRX 411) / Annovis Bio
Enrollment change: Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) (clinicaltrials.gov) - Feb 11, 2014
P1, N=0, Withdrawn, Sponsor: Thomas S. Scanlan
Recruiting --> Withdrawn N=10 --> 0
- New P2 trial: Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients (clinicaltrials.gov) - Feb 10, 2014
P2, N=15, Not yet recruiting, Sponsor: Erasmus Medical Center
- Lumigan (bimatoprost) / Senju, AbbVie
New P4 trial: Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (clinicaltrials.gov) - Feb 9, 2014
P4, N=31, Not yet recruiting, Sponsor: Cardiff University
- Enrollment open, Surgery: TABLAS: Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery? (clinicaltrials.gov) - Feb 9, 2014
P=N/A, N=458, Recruiting, Sponsor: Karolinska Institutet
N=10 --> 0 Not yet recruiting --> Recruiting
- Trial completion: Investigating the Role of EN in NTIS Among Fistula Patients (clinicaltrials.gov) - Feb 7, 2014
P=N/A, N=40, Completed, Sponsor: Jinling Hospital, China
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=150, Completed, Sponsor: Yonsei University
Recruiting --> Completed N=100 --> 150
- | New P1/2 trial: A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=105, Completed, Sponsor: Royal Marsden NHS Foundation Trust
- Trial completion: A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=105, Completed, Sponsor: Royal Marsden NHS Foundation Trust
N=100 --> 150 Not yet recruiting --> Completed
- Trial completion: Comparative Study of Surgical Completeness After Robotic Thyroidectomy Versus Conventional Open Thyroidectomy (clinicaltrials.gov) - Feb 3, 2014
P=N/A, N=150, Completed, Sponsor: Yonsei University
Not yet recruiting --> Completed Recruiting --> Completed
- prednisone / Generic mfg.
Enrollment change: Short-term Prednisone to Treat STA Study(SPTSS) (clinicaltrials.gov) - Jan 29, 2014
P4, N=40, Recruiting, Sponsor: Xinqiao Hospital of Chongqing
Recruiting --> Completed N=50 --> 40
- Enrollment change: Investigating the Role of EN in NTIS Among Fistula Patients (clinicaltrials.gov) - Jan 26, 2014
P=N/A, N=40, Completed, Sponsor: Jinling Hospital, China
N=50 --> 40 N=30 --> 40
- temozolomide / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Metastases: Capecitabine and Temozolomide for Neuroendocrine Cancers (clinicaltrials.gov) - Jan 21, 2014
P2, N=38, Active, not recruiting, Sponsor: Columbia University
N=30 --> 40 Recruiting --> Active, not recruiting
- Biomarker, Enrollment change: Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=1, Completed, Sponsor: Norman Eberhardt
Recruiting --> Active, not recruiting N=1000 --> 1